drugset
drugset / Trial / NCT01174082

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

NCT01174082 ↗

Phase 2 Terminated 2 enrolled M.D. Anderson Cancer Center
RandomizedSingle-groupTriple-blindTreatment

Summary

The goal of this clinical research study is to learn if vaccinating a donor with your purified myeloma protein and then injecting it back into you will help your immune system control the multiple myeloma.

Timeline

Start
2010-07-20
Primary completion
2017-02-23
Completion
2017-02-23

Outcome

Outcome not reported

Stopped (Enrollment): “Slow Accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject KLH Vaccine Vaccine 0.5 ml Subcutaneous
Subject KLH-id Vaccine Vaccine 0.5 ml Subcutaneous
Background GM-CSF Protein / enzyme biologic 250 ug/m2 Subcutaneous

Indications

plasma cell myeloma